Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

The Connecticut Retirement Plans & Trust Funds brought an action against Amgen ... that the pharmaceutical giant purportedly made to the FDA regarding the safety of two products.

As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.

Oct 22 (Reuters) - Amgen (AMGN.O), opens new tab will launch ... biologic drugs that are comparable to generics of traditional pharmaceuticals. Unlike traditional drugs, complex biologic drugs ...

Oct 30 (Reuters) - Amgen (AMGN.O), opens new tab reported a higher quarterly profit on Wednesday, driven by a 24% rise in sales of drugs for high cholesterol and osteoporosis, and said mid-stage ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. At the same time ...

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.

Amgen is one of the world's largest biotechnology ... GSK is one of the world's largest pharma companies. Leading products include Advair for asthma, Ventolin for bronchospasm and Theraflu for ...